 Irene Schauer
Concepts (308)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 16 | 2024 | 3715 | 1.100 |
Why?
| | Insulin Resistance | 13 | 2024 | 1208 | 1.000 |
Why?
| | Mitochondria, Muscle | 2 | 2024 | 116 | 0.930 |
Why?
| | Hyperinsulinism | 4 | 2022 | 121 | 0.910 |
Why?
| | Hyperlipidemias | 3 | 2022 | 120 | 0.850 |
Why?
| | Luteinizing Hormone | 4 | 2022 | 185 | 0.750 |
Why?
| | Vascular Stiffness | 3 | 2024 | 494 | 0.730 |
Why?
| | Follicle Stimulating Hormone | 4 | 2022 | 244 | 0.720 |
Why?
| | Metabolic Syndrome | 3 | 2021 | 354 | 0.670 |
Why?
| | Insulin | 10 | 2022 | 2409 | 0.640 |
Why?
| | Diabetes Mellitus, Type 2 | 9 | 2024 | 2531 | 0.540 |
Why?
| | Fatty Acids, Nonesterified | 3 | 2021 | 159 | 0.540 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2010 | 446 | 0.520 |
Why?
| | Cross-Over Studies | 6 | 2024 | 564 | 0.500 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 3 | 2014 | 145 | 0.410 |
Why?
| | Diabetic Angiopathies | 4 | 2017 | 259 | 0.340 |
Why?
| | Lipoproteins, LDL | 1 | 2010 | 116 | 0.320 |
Why?
| | Exercise | 6 | 2024 | 2057 | 0.300 |
Why?
| | Muscle, Skeletal | 7 | 2024 | 1724 | 0.300 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 261 | 0.280 |
Why?
| | Cardiovascular Diseases | 7 | 2024 | 2111 | 0.270 |
Why?
| | Fatty Acids | 1 | 2010 | 443 | 0.270 |
Why?
| | Bromocriptine | 2 | 2022 | 30 | 0.250 |
Why?
| | Glucose Clamp Technique | 7 | 2021 | 195 | 0.240 |
Why?
| | Atherosclerosis | 1 | 2010 | 415 | 0.240 |
Why?
| | Lipids | 5 | 2022 | 672 | 0.240 |
Why?
| | Pulse Wave Analysis | 2 | 2023 | 272 | 0.230 |
Why?
| | Adult | 26 | 2024 | 37929 | 0.220 |
Why?
| | Hypertension | 4 | 2010 | 1295 | 0.220 |
Why?
| | Blood Glucose | 7 | 2024 | 2186 | 0.220 |
Why?
| | Adipose Tissue, Brown | 1 | 2024 | 53 | 0.210 |
Why?
| | Young Adult | 9 | 2024 | 13209 | 0.210 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 91 | 0.210 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2024 | 135 | 0.200 |
Why?
| | Cardiorespiratory Fitness | 2 | 2024 | 55 | 0.200 |
Why?
| | Oxygen | 2 | 2018 | 931 | 0.200 |
Why?
| | Glucose Intolerance | 1 | 2024 | 146 | 0.190 |
Why?
| | Female | 29 | 2024 | 73304 | 0.190 |
Why?
| | Glycolysis | 1 | 2024 | 321 | 0.190 |
Why?
| | Case-Control Studies | 4 | 2024 | 3556 | 0.190 |
Why?
| | Signal Transduction | 2 | 2021 | 5079 | 0.190 |
Why?
| | Human Growth Hormone | 1 | 2022 | 48 | 0.180 |
Why?
| | Leg | 2 | 2021 | 236 | 0.180 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2024 | 611 | 0.180 |
Why?
| | Humans | 41 | 2024 | 137585 | 0.180 |
Why?
| | Soybean Oil | 1 | 2021 | 14 | 0.180 |
Why?
| | Resistance Training | 1 | 2024 | 164 | 0.180 |
Why?
| | Adolescent | 14 | 2024 | 21513 | 0.180 |
Why?
| | Middle Aged | 19 | 2024 | 33479 | 0.180 |
Why?
| | Cyclins | 3 | 1997 | 91 | 0.170 |
Why?
| | Oxidative Phosphorylation | 2 | 2019 | 193 | 0.170 |
Why?
| | Incretins | 1 | 2020 | 22 | 0.170 |
Why?
| | Male | 27 | 2024 | 67762 | 0.170 |
Why?
| | Obesity | 4 | 2023 | 2992 | 0.160 |
Why?
| | Dietary Fats | 3 | 2012 | 304 | 0.160 |
Why?
| | Bone Remodeling | 1 | 2020 | 75 | 0.160 |
Why?
| | Bone Resorption | 1 | 2020 | 86 | 0.160 |
Why?
| | Exercise Tolerance | 2 | 2024 | 279 | 0.160 |
Why?
| | Phospholipids | 1 | 2021 | 223 | 0.160 |
Why?
| | Retinoblastoma Protein | 2 | 2001 | 57 | 0.160 |
Why?
| | Sitagliptin Phosphate | 1 | 2019 | 33 | 0.150 |
Why?
| | Glucose | 2 | 2024 | 1020 | 0.150 |
Why?
| | Diastole | 1 | 2019 | 149 | 0.150 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 47 | 0.150 |
Why?
| | Coronary Vessels | 2 | 2010 | 248 | 0.150 |
Why?
| | Osteogenesis | 1 | 2020 | 188 | 0.150 |
Why?
| | Hyperglycemia | 1 | 2022 | 347 | 0.150 |
Why?
| | Cell Cycle Proteins | 3 | 1998 | 617 | 0.150 |
Why?
| | Cancellous Bone | 1 | 2017 | 23 | 0.140 |
Why?
| | Lipoproteins | 3 | 2010 | 168 | 0.140 |
Why?
| | Sleep | 1 | 2024 | 755 | 0.140 |
Why?
| | Body Fat Distribution | 1 | 2017 | 49 | 0.130 |
Why?
| | Tumor Suppressor Proteins | 2 | 1997 | 327 | 0.130 |
Why?
| | Pericardium | 1 | 2017 | 55 | 0.130 |
Why?
| | Subcutaneous Fat | 1 | 2017 | 81 | 0.130 |
Why?
| | Aorta | 2 | 2010 | 417 | 0.130 |
Why?
| | Heart Failure | 1 | 2010 | 2236 | 0.130 |
Why?
| | Microvessels | 1 | 2017 | 88 | 0.130 |
Why?
| | Hyperlipoproteinemias | 2 | 1987 | 6 | 0.120 |
Why?
| | Cell Cycle | 2 | 1996 | 601 | 0.120 |
Why?
| | Adiponectin | 2 | 2022 | 244 | 0.120 |
Why?
| | Phosphorylation | 3 | 2010 | 1759 | 0.120 |
Why?
| | Oxygen Consumption | 4 | 2021 | 696 | 0.120 |
Why?
| | Blood Vessels | 1 | 2017 | 187 | 0.120 |
Why?
| | Absorptiometry, Photon | 2 | 2017 | 259 | 0.110 |
Why?
| | Cell Division | 4 | 2009 | 794 | 0.110 |
Why?
| | Glycerol | 3 | 2012 | 94 | 0.110 |
Why?
| | Calcium | 2 | 2010 | 1199 | 0.110 |
Why?
| | Coronary Artery Disease | 2 | 2011 | 698 | 0.110 |
Why?
| | Oncogene Proteins | 1 | 1994 | 59 | 0.110 |
Why?
| | Carcinoma, Small Cell | 1 | 1994 | 172 | 0.110 |
Why?
| | Body Composition | 2 | 2024 | 684 | 0.110 |
Why?
| | Double-Blind Method | 3 | 2024 | 1993 | 0.100 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2012 | 54 | 0.100 |
Why?
| | Cholesterol | 4 | 2010 | 410 | 0.100 |
Why?
| | Liver | 2 | 2012 | 1943 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 1996 | 2526 | 0.090 |
Why?
| | Cells, Cultured | 2 | 2010 | 4193 | 0.090 |
Why?
| | Caenorhabditis | 1 | 1990 | 3 | 0.090 |
Why?
| | Adipose Tissue | 2 | 2018 | 635 | 0.090 |
Why?
| | Gonadotropin-Releasing Hormone | 2 | 2024 | 212 | 0.090 |
Why?
| | Adipocytes | 1 | 2012 | 222 | 0.090 |
Why?
| | Triglycerides | 8 | 2012 | 524 | 0.090 |
Why?
| | Professional-Patient Relations | 1 | 2012 | 145 | 0.080 |
Why?
| | Cohort Studies | 4 | 2018 | 5742 | 0.080 |
Why?
| | Creatinine | 2 | 2022 | 499 | 0.080 |
Why?
| | Embryo, Nonmammalian | 1 | 1990 | 167 | 0.080 |
Why?
| | Rats, Inbred SHR | 1 | 2010 | 45 | 0.080 |
Why?
| | Receptors, LDL | 1 | 2010 | 47 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 125 | 0.080 |
Why?
| | Free Radical Scavengers | 1 | 2010 | 88 | 0.080 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2010 | 162 | 0.080 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 171 | 0.080 |
Why?
| | Age Factors | 4 | 2012 | 3295 | 0.080 |
Why?
| | Reference Values | 1 | 2010 | 816 | 0.080 |
Why?
| | Calcinosis | 1 | 2011 | 235 | 0.080 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2010 | 283 | 0.080 |
Why?
| | Spleen | 1 | 2010 | 514 | 0.070 |
Why?
| | Counseling | 1 | 2012 | 391 | 0.070 |
Why?
| | Cyclin D1 | 2 | 2001 | 68 | 0.070 |
Why?
| | Enzyme Activation | 1 | 2010 | 810 | 0.070 |
Why?
| | Propranolol | 3 | 1987 | 50 | 0.070 |
Why?
| | Sex Characteristics | 3 | 2022 | 762 | 0.070 |
Why?
| | Environmental Monitoring | 1 | 2010 | 370 | 0.070 |
Why?
| | Phosphatidylcholine-Sterol O-Acyltransferase | 3 | 1985 | 5 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2010 | 437 | 0.070 |
Why?
| | Mitochondria | 1 | 2014 | 948 | 0.070 |
Why?
| | Down-Regulation | 1 | 2010 | 657 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2010 | 622 | 0.070 |
Why?
| | Cell Nucleus | 1 | 2010 | 620 | 0.060 |
Why?
| | Cattle | 1 | 2009 | 984 | 0.060 |
Why?
| | Energy Metabolism | 2 | 2024 | 922 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 1994 | 1081 | 0.060 |
Why?
| | Diabetes Mellitus | 1 | 2014 | 1040 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 1 | 1987 | 323 | 0.060 |
Why?
| | Body Mass Index | 3 | 2021 | 2389 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2486 | 0.050 |
Why?
| | Transcription, Genetic | 1 | 1990 | 1457 | 0.050 |
Why?
| | Heparin | 2 | 2022 | 261 | 0.050 |
Why?
| | Thermogenesis | 1 | 2024 | 44 | 0.050 |
Why?
| | Sex Factors | 4 | 2018 | 2071 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 916 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 1983 | 88 | 0.050 |
Why?
| | Actigraphy | 1 | 2024 | 110 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2010 | 2691 | 0.050 |
Why?
| | Intra-Abdominal Fat | 2 | 2017 | 91 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2010 | 3015 | 0.050 |
Why?
| | Cold Temperature | 1 | 2024 | 179 | 0.050 |
Why?
| | Pituitary Hormones | 1 | 2022 | 16 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2024 | 366 | 0.050 |
Why?
| | Child | 6 | 2024 | 21935 | 0.050 |
Why?
| | Time Factors | 2 | 2010 | 6828 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2024 | 294 | 0.050 |
Why?
| | Prolactin | 1 | 2022 | 96 | 0.050 |
Why?
| | Growth Hormone | 1 | 2022 | 101 | 0.050 |
Why?
| | Thyroid Hormones | 1 | 2022 | 61 | 0.050 |
Why?
| | Thyrotropin | 1 | 2022 | 114 | 0.050 |
Why?
| | Cholesterol, HDL | 5 | 2011 | 203 | 0.050 |
Why?
| | Coronary Disease | 1 | 1983 | 385 | 0.040 |
Why?
| | Transcription Factor CHOP | 1 | 2021 | 31 | 0.040 |
Why?
| | Muscle Strength | 1 | 2024 | 317 | 0.040 |
Why?
| | Rats | 1 | 2010 | 5647 | 0.040 |
Why?
| | Emulsions | 1 | 2021 | 53 | 0.040 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2021 | 30 | 0.040 |
Why?
| | Primary Health Care | 1 | 2012 | 1738 | 0.040 |
Why?
| | Longevity | 1 | 2022 | 165 | 0.040 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2022 | 135 | 0.040 |
Why?
| | Estrogens | 1 | 2024 | 367 | 0.040 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 267 | 0.040 |
Why?
| | Glucagon-Like Peptide 2 | 1 | 2020 | 2 | 0.040 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2020 | 14 | 0.040 |
Why?
| | Thinness | 1 | 2021 | 91 | 0.040 |
Why?
| | Leptin | 1 | 2022 | 236 | 0.040 |
Why?
| | Genetic Fitness | 1 | 2021 | 59 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2021 | 148 | 0.040 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2021 | 110 | 0.040 |
Why?
| | Heat-Shock Proteins | 1 | 2021 | 143 | 0.040 |
Why?
| | Risk Assessment | 1 | 2010 | 3457 | 0.040 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 172 | 0.040 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 319 | 0.040 |
Why?
| | Hydrocortisone | 1 | 2022 | 322 | 0.040 |
Why?
| | Animals | 4 | 2010 | 36940 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 1997 | 69 | 0.040 |
Why?
| | Aging | 1 | 2010 | 1864 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4295 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 2 | 1997 | 121 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 5757 | 0.040 |
Why?
| | Sulfonylurea Compounds | 1 | 2019 | 48 | 0.040 |
Why?
| | Placebos | 1 | 2019 | 199 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 558 | 0.040 |
Why?
| | Aged | 4 | 2022 | 23961 | 0.040 |
Why?
| | Cross-Sectional Studies | 3 | 2017 | 5472 | 0.040 |
Why?
| | Fungal Proteins | 1 | 1998 | 123 | 0.040 |
Why?
| | Cell Respiration | 1 | 2018 | 103 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2021 | 512 | 0.040 |
Why?
| | CDC2-CDC28 Kinases | 1 | 1997 | 18 | 0.030 |
Why?
| | Capillary Resistance | 1 | 2017 | 5 | 0.030 |
Why?
| | Obesity, Abdominal | 1 | 2017 | 48 | 0.030 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2017 | 20 | 0.030 |
Why?
| | Research Design | 1 | 2024 | 1139 | 0.030 |
Why?
| | Oxyhemoglobins | 1 | 2017 | 23 | 0.030 |
Why?
| | Anthropometry | 1 | 2017 | 213 | 0.030 |
Why?
| | Random Allocation | 1 | 2018 | 353 | 0.030 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2017 | 59 | 0.030 |
Why?
| | Adiposity | 2 | 2012 | 518 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2022 | 641 | 0.030 |
Why?
| | Microcirculation | 1 | 2017 | 149 | 0.030 |
Why?
| | Tumor Cells, Cultured | 2 | 1997 | 955 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 1996 | 16 | 0.030 |
Why?
| | Molecular Weight | 2 | 2012 | 335 | 0.030 |
Why?
| | Microtubule-Associated Proteins | 1 | 1997 | 196 | 0.030 |
Why?
| | Bicycling | 1 | 2017 | 114 | 0.030 |
Why?
| | Hip Joint | 1 | 2017 | 171 | 0.030 |
Why?
| | Genes, Tumor Suppressor | 1 | 1996 | 86 | 0.030 |
Why?
| | Progesterone | 1 | 1997 | 254 | 0.030 |
Why?
| | Gene Expression | 1 | 2021 | 1502 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2017 | 375 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2017 | 246 | 0.030 |
Why?
| | Waist Circumference | 1 | 2015 | 143 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 2017 | 474 | 0.030 |
Why?
| | Hemoglobins | 1 | 2017 | 353 | 0.030 |
Why?
| | Osteoporosis | 1 | 2017 | 243 | 0.030 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1998 | 405 | 0.030 |
Why?
| | Mice | 2 | 2010 | 17787 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2021 | 1317 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 1998 | 557 | 0.030 |
Why?
| | Bone Density | 1 | 2017 | 489 | 0.030 |
Why?
| | Blood Pressure | 2 | 2017 | 1786 | 0.030 |
Why?
| | Exercise Therapy | 1 | 2018 | 443 | 0.030 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 204 | 0.030 |
Why?
| | Cytokines | 1 | 2021 | 2085 | 0.020 |
Why?
| | Risk | 2 | 1987 | 912 | 0.020 |
Why?
| | Risk Factors | 3 | 2012 | 10388 | 0.020 |
Why?
| | Protein Kinases | 1 | 1994 | 319 | 0.020 |
Why?
| | Abdominal Fat | 1 | 2012 | 41 | 0.020 |
Why?
| | Models, Statistical | 1 | 2015 | 669 | 0.020 |
Why?
| | Autoradiography | 1 | 1990 | 78 | 0.020 |
Why?
| | Electrophoresis | 1 | 1990 | 32 | 0.020 |
Why?
| | DNA Probes | 1 | 1990 | 60 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2012 | 155 | 0.020 |
Why?
| | Lipoproteins, HDL | 2 | 1981 | 77 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2031 | 0.020 |
Why?
| | Health Expenditures | 1 | 2012 | 189 | 0.020 |
Why?
| | Nucleotides | 1 | 1990 | 125 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1291 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 553 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2012 | 565 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 375 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 6763 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 530 | 0.020 |
Why?
| | Lung | 1 | 2001 | 4060 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 433 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 1997 | 2607 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1704 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5131 | 0.020 |
Why?
| | Transcription Factors | 1 | 1996 | 1719 | 0.020 |
Why?
| | Atenolol | 1 | 1987 | 7 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2012 | 556 | 0.020 |
Why?
| | Metoprolol | 1 | 1987 | 40 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1289 | 0.020 |
Why?
| | Patient Selection | 1 | 2010 | 696 | 0.020 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 445 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 1997 | 2253 | 0.010 |
Why?
| | Diet | 1 | 2012 | 1278 | 0.010 |
Why?
| | Diet, Sodium-Restricted | 1 | 1983 | 36 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 7604 | 0.010 |
Why?
| | Physical Exertion | 1 | 1983 | 215 | 0.010 |
Why?
| | Smoking Prevention | 1 | 1983 | 184 | 0.010 |
Why?
| | Autoanalysis | 1 | 1981 | 8 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1983 | 1236 | 0.010 |
Why?
| | Lipoprotein Lipase | 1 | 1980 | 59 | 0.010 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 1979 | 33 | 0.010 |
Why?
| | Contraceptives, Oral | 1 | 1979 | 43 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 5778 | 0.010 |
Why?
| | Hybrid Cells | 1 | 1998 | 49 | 0.010 |
Why?
| | Genetic Complementation Test | 1 | 1998 | 67 | 0.010 |
Why?
| | Precipitin Tests | 1 | 1998 | 100 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2001 | 1272 | 0.010 |
Why?
| | Cyclin B | 1 | 1997 | 15 | 0.010 |
Why?
| | Promegestone | 1 | 1997 | 33 | 0.010 |
Why?
| | Cyclin A | 1 | 1997 | 17 | 0.010 |
Why?
| | Gonanes | 1 | 1997 | 27 | 0.010 |
Why?
| | Mifepristone | 1 | 1997 | 64 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 1997 | 34 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 1997 | 75 | 0.010 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 1997 | 39 | 0.010 |
Why?
| | G1 Phase | 1 | 1997 | 71 | 0.010 |
Why?
| | Epidermal Growth Factor | 1 | 1997 | 177 | 0.010 |
Why?
| | Drug Synergism | 1 | 1997 | 382 | 0.010 |
Why?
| | Cyclin-Dependent Kinases | 1 | 1997 | 132 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 1983 | 1046 | 0.010 |
Why?
| | Cell Line | 1 | 2001 | 2847 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2001 | 1096 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1998 | 2139 | 0.010 |
Why?
| | United States | 1 | 2012 | 14841 | 0.010 |
Why?
| | ErbB Receptors | 1 | 1997 | 614 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2900 | 0.010 |
Why?
| | Biomarkers | 1 | 2001 | 4149 | 0.010 |
Why?
| | Mutation | 1 | 1998 | 3958 | 0.000 |
Why?
| | Cholesterol Esters | 1 | 1985 | 8 | 0.000 |
Why?
| | Lipoproteins, VLDL | 1 | 1984 | 18 | 0.000 |
Why?
| | Injections, Intravenous | 1 | 1984 | 206 | 0.000 |
Why?
| | Microchemistry | 1 | 1981 | 20 | 0.000 |
Why?
| | Regression Analysis | 1 | 1984 | 1024 | 0.000 |
Why?
| | Capillaries | 1 | 1981 | 108 | 0.000 |
Why?
| | Germany, East | 1 | 1979 | 1 | 0.000 |
Why?
| | Occupational Medicine | 1 | 1979 | 10 | 0.000 |
Why?
| | Child, Preschool | 1 | 1981 | 11074 | 0.000 |
Why?
|
|
Schauer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|